Prestige Consumer Healthcare Reports FY26 Revenue & EPS Decline, Announces $150M Acquisition, Boosts Share Buybacks
PBH is trading near its 52-week low of $42.62 (7.8% above the low) on elevated volume (4.5× avg).
Summary
Prestige Consumer Healthcare reported a decline in full-year revenue and earnings, alongside a significant supplier loan write-off. The company simultaneously announced a new $150 million acquisition and substantially increased its share repurchases, leading to a projected doubling of its debt.
Key Events · Earnings and Guidance · PBH
-
Full-Year Financial Decline
Reported a 4.3% decrease in revenue to $1.089 billion and an 11% drop in net income and EPS for fiscal 2026 compared to the prior year.
-
Gross Margin Contraction
Gross profit margin decreased to 54.7% in 2026 from 55.8% in 2025, partly due to costs related to the acquisition of a Canadian manufacturing facility.
-
Strategic Acquisitions & Debt Increase
Completed the Pillar5 Pharma Inc. acquisition for $109.9 million and announced a definitive agreement to acquire LaCorium Health for $150.0 million, which is expected to increase total indebtedness from $1.0 billion to $2.2 billion.
-
Significant Share Repurchases
Repurchased $156.3 million in common stock during fiscal 2026, a substantial increase from $51.5 million in the prior year.
Analysis · PBH · Life Sciences
Prestige Consumer Healthcare reported a 4.3% decline in fiscal 2026 revenue and an 11% drop in net income and EPS, alongside a decrease in gross profit margin. The company also recorded a $10.3 million write-off from a supplier loan. Despite these operational headwinds, the company significantly increased its share repurchase program to $156.3 million and announced a $150 million acquisition of LaCorium Health, which will nearly double its total indebtedness to $2.2 billion. Ongoing supply chain issues, particularly in eye care, continue to impact sales.
At the time of this filing, PBH was trading at $45.93 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $42.62 to $89.37. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.